BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

142 related articles for article (PubMed ID: 25142285)

  • 1. Stimulation of invariant natural killer T cells by α-Galactosylceramide activates the JAK-STAT pathway in endothelial cells and reduces angiogenesis in the 5T33 multiple myeloma model.
    Nur H; Rao L; Frassanito MA; De Raeve H; Ribatti D; Mfopou JK; Van Valckenborgh E; De Bruyne E; Vacca A; Vanderkerken K; Menu E
    Br J Haematol; 2014 Dec; 167(5):651-63. PubMed ID: 25142285
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Administration of anti-CD25 mAb leads to impaired α-galactosylceramide-mediated induction of IFN-γ production in a murine model.
    Rosalia RA; Štěpánek I; Polláková V; Šímová J; Bieblová J; Indrová M; Moravcová S; Přibylová H; Bontkes HJ; Bubeník J; Sparwasser T; Reiniš M
    Immunobiology; 2013 Jun; 218(6):851-9. PubMed ID: 23182710
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Preclinical evaluation of invariant natural killer T cells in the 5T33 multiple myeloma model.
    Nur H; Fostier K; Aspeslagh S; Renmans W; Bertrand E; Leleu X; Favreau M; Breckpot K; Schots R; De Waele M; Van Valckenborgh E; De Bruyne E; Facon T; Elewaut D; Vanderkerken K; Menu E
    PLoS One; 2013; 8(5):e65075. PubMed ID: 23741460
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Activation of human invariant natural killer T cells with a thioglycoside analogue of α-galactosylceramide.
    Hogan AE; O'Reilly V; Dunne MR; Dere RT; Zeng SG; O'Brien C; Amu S; Fallon PG; Exley MA; O'Farrelly C; Zhu X; Doherty DG
    Clin Immunol; 2011 Aug; 140(2):196-207. PubMed ID: 21493160
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Tumor cells loaded with α-galactosylceramide promote therapeutic NKT-dependent anti-tumor immunity in multiple myeloma.
    Hong S; Lee H; Jung K; Lee SM; Lee SJ; Jun HJ; Kim Y; Song H; Bogen B; Choi I
    Immunol Lett; 2013; 156(1-2):132-9. PubMed ID: 24148970
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Production of both IL-27 and IFN-gamma after the treatment with a ligand for invariant NK T cells is responsible for the suppression of Th2 response and allergic inflammation in a mouse experimental asthma model.
    Fujita H; Teng A; Nozawa R; Takamoto-Matsui Y; Katagiri-Matsumura H; Ikezawa Z; Ishii Y
    J Immunol; 2009 Jul; 183(1):254-60. PubMed ID: 19542437
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Deficient invariant natural killer T cells had impaired regulation on osteoclastogenesis in myeloma bone disease.
    Jiang F; Liu H; Liu Z; Yan S; Chen J; Shao Q; Li L; Song J; Wang G; Shao Z; Fu R
    J Cell Mol Med; 2018 May; 22(5):2706-2716. PubMed ID: 29473714
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Activation of invariant natural killer T cells by α-galactosylceramide ameliorates myocardial ischemia/reperfusion injury in mice.
    Homma T; Kinugawa S; Takahashi M; Sobirin MA; Saito A; Fukushima A; Suga T; Takada S; Kadoguchi T; Masaki Y; Furihata T; Taniguchi M; Nakayama T; Ishimori N; Iwabuchi K; Tsutsui H
    J Mol Cell Cardiol; 2013 Sep; 62():179-88. PubMed ID: 23774048
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Activation of invariant natural killer T cells impedes liver regeneration by way of both IFN-γ- and IL-4-dependent mechanisms.
    Yin S; Wang H; Bertola A; Feng D; Xu MJ; Wang Y; Gao B
    Hepatology; 2014 Oct; 60(4):1356-66. PubMed ID: 24623351
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Activated iNKT cells promote Vγ9Vδ2-T cell anti-tumor effector functions through the production of TNF-α.
    Schneiders FL; de Bruin RC; Santegoets SJ; Bonneville M; Scotet E; Scheper RJ; Verheul HM; de Gruijl TD; van der Vliet HJ
    Clin Immunol; 2012 Feb; 142(2):194-200. PubMed ID: 22122798
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Generation of antitumor invariant natural killer T cell lines in multiple myeloma and promotion of their functions via lenalidomide: a strategy for immunotherapy.
    Song W; van der Vliet HJ; Tai YT; Prabhala R; Wang R; Podar K; Catley L; Shammas MA; Anderson KC; Balk SP; Exley MA; Munshi NC
    Clin Cancer Res; 2008 Nov; 14(21):6955-62. PubMed ID: 18980990
    [TBL] [Abstract][Full Text] [Related]  

  • 12. In vivo activation of invariant V alpha 14 natural killer T cells by alpha-galactosylceramide sequentially induces Fas-dependent and -independent cytotoxicity.
    Lisbonne M; Hachem P; Tonanny MB; Fourneau JM; Sidobre S; Kronenberg M; Van Endert P; Dy M; Schneider E; Leite-de-Moraes MC
    Eur J Immunol; 2004 May; 34(5):1381-8. PubMed ID: 15114671
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Activation of invariant NKT cells confers protection against Chlamydia trachomatis-induced arthritis.
    Bharhani MS; Chiu B; Na KS; Inman RD
    Int Immunol; 2009 Jul; 21(7):859-70. PubMed ID: 19477915
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Natural Killer T-Cell Agonist α-Galactosylceramide and PD-1 Blockade Synergize to Reduce Tumor Development in a Preclinical Model of Colon Cancer.
    Wang Y; Bhave MS; Yagita H; Cardell SL
    Front Immunol; 2020; 11():581301. PubMed ID: 33193386
    [TBL] [Abstract][Full Text] [Related]  

  • 15. In vitro anti-tumour activity of alpha-galactosylceramide-stimulated human invariant Valpha24+NKT cells against melanoma.
    Kikuchi A; Nieda M; Schmidt C; Koezuka Y; Ishihara S; Ishikawa Y; Tadokoro K; Durrant S; Boyd A; Juji T; Nicol A
    Br J Cancer; 2001 Sep; 85(5):741-6. PubMed ID: 11531261
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Key role for respiratory CD103(+) dendritic cells, IFN-γ, and IL-17 in protection against Streptococcus pneumoniae infection in response to α-galactosylceramide.
    Ivanov S; Fontaine J; Paget C; Macho Fernandez E; Van Maele L; Renneson J; Maillet I; Wolf NM; Rial A; Léger H; Ryffel B; Frisch B; Chabalgoity JA; Sirard JC; Benecke A; Faveeuw C; Trottein F
    J Infect Dis; 2012 Sep; 206(5):723-34. PubMed ID: 22723642
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Alpha-galactosylceramide modulates the induction of indoleamine 2,3-dioxygenase in antigen presenting cells.
    Fallarini S; Paoletti T; Panza L; Lombardi G
    Biochem Pharmacol; 2008 Sep; 76(6):738-50. PubMed ID: 18671950
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Hyporesponsiveness to natural killer T-cell ligand alpha-galactosylceramide in cancer-bearing state mediated by CD11b+ Gr-1+ cells producing nitric oxide.
    Yanagisawa K; Exley MA; Jiang X; Ohkochi N; Taniguchi M; Seino K
    Cancer Res; 2006 Dec; 66(23):11441-6. PubMed ID: 17145891
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Exogenous Activation of Invariant Natural Killer T Cells by α-Galactosylceramide Reduces Pneumococcal Outgrowth and Dissemination Postinfluenza.
    Barthelemy A; Ivanov S; Hassane M; Fontaine J; Heurtault B; Frisch B; Faveeuw C; Paget C; Trottein F
    mBio; 2016 Nov; 7(6):. PubMed ID: 27803187
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Altered invariant natural killer T cell subsets and its functions in patients with oral squamous cell carcinoma.
    Singh AK; Shukla NK; Das SN
    Scand J Immunol; 2013 Nov; 78(5):468-77. PubMed ID: 23980793
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.